Up 27% over 12 months, this S&P/ASX 200 Index (ASX: XJO) healthcare share is charging higher again today, up 2.1% in morning trade to $9.73 a share.
For some context, the ASX 200 is up 0.08% at this same time.
This comes after the healthcare company revealed that it may list on the Nasdaq Composite Index (INDEXNASDAQ: .IXIC).
Any guesses which?
If you said ASX 200 healthcare share Telix Pharmaceuticals Ltd (ASX: TLX), go to the front of the virtual class.
Here's what we know so far.
ASX 200 healthcare share mulls Nasdaq listing
This morning, Telix Pharmaceuticals reported that it's considering an initial public offering (IPO) in the United States and listing on the tech-focused Nasdaq.
This will involve the issuance of American Depositary Shares (ADS) representing Telix's ordinary shares.
However, a lot of uncertainty as to the outcome and potential pricing of the ADS for the ASX 200 healthcare share remains.
Management reported it has not yet finalised how many ADS may be offered, the number of underlying ordinary shares that may be issued, the price for such instruments or the timing of the offering.
In moving forward, the company expects to file a registration statement relating to its ADS to be sold in the proposed offering with the US Securities and Exchange Commission (SEC).
The company noted, "Any securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective, which is subject to a US SEC review process, market conditions, investor demand and customary corporate approvals."
Management also highlighted that no final decision has been made relating to the Nasdaq listing and IPO.
Telix Pharmaceuticals share price snapshot
The Telix Pharmaceuticals share price has struggled over the past six months, down 10%.
Still, the ASX 200 healthcare share remains up a very healthy 27% over the past full year.
Investors who snapped up the stock five years ago will be sitting on an eye-watering gain of 1,222%.
